VBI Vaccines

Name

VBI Vaccines

Legal name

VBI Vaccines Inc.

Website

https://www.vbivaccines.com/

Company type

Public

Founded year

2005

Operating status

Closed

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Vaccines biopharmaceutical
• Virus-like particles
• Hepatitis B vaccine
• Immunotherapeutic candidates
• Vaccine development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. PreHevbrio/Sci-B-Vac Sales: Commercial sales of PreHevbrio (3-antigen hepatitis B vaccine) approved in U.S., Israel, E.U., EEA, U.K., and Canada. However, the company has discontinued operations and issued a voluntary recall of all PreHevbrio vaccine as of November 2024.
2. License and Collaboration Agreement with Brii Biosciences: VBI received $11 million upfront (including $4 million payment and $7 million equity investment at $3.05/share) from Brii Biosciences for VBI-2601 development. Eligible for additional $117.5 million in milestone payments plus potential double-digit royalties on commercial sales in China, Taiwan, Macau, and Hong Kong.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

VBI Vaccines develops vaccine and immunotherapeutic candidates using three proprietary virus-like particle (VLP) technology platforms: VLPs, enveloped VLPs (eVLPs), and mRNA-launched eVLPs (MLE). The company's lead commercial product PreHevbrio/Sci-B-Vac is a 3-antigen hepatitis B vaccine approved in the U.S., Israel, E.U./EEA, U.K., and Canada. Pipeline includes prophylactic candidates for cytomegalovirus, COVID-19 variants, and Zika, plus therapeutic candidates for chronic hepatitis B (VBI-2601) and glioblastoma (VBI-1901).

Product overview

VBI Vaccines is a biopharmaceutical company developing vaccine and immunotherapeutic candidates using three VLP technology platforms: VLPs (virus-like particles), eVLPs (enveloped VLPs), and MLE (mRNA-launched eVLPs). The product portfolio includes PreHevbrio/Sci-B-Vac, a 3-antigen hepatitis B vaccine (the company's only approved commercial product, now recalled and discontinued in November 2024 due to company bankruptcy); prophylactic vaccine candidates targeting cytomegalovirus (VBI-1501), COVID-19/coronavirus variants (VBI-2901, VBI-2902, VBI-2905), and Zika (VBI-2501); and therapeutic immunotherapeutic candidates including VBI-2601 (BRII-179) for chronic hepatitis B and VBI-1901 for glioblastoma.

Differentiator

Problem solved

Functional benefit

Brands

• Sci-B-Vac: Hepatitis B vaccine brand name approved in Israel and 10 other countries, containing all three viral surface antigens of hepatitis B virus
• PreHevbrio

Products and services

• PreHevbrio (Sci-B-Vac) A 3-antigen hepatitis B vaccine (recombinant) indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. Approved in the U.S., Israel, E.U./EEA/U.K., and Canada. Marketed as Sci-B-Vac in Israel and 10 other countries. The first and only approved 3-antigen hepatitis B vaccine in the U.S., E.U., and Canada, with Phase 3 PROTECT study demonstrating superiority over Engerix-B in adults 45+.
• VBI-2601 (BRII-179) An immunotherapeutic candidate for chronic hepatitis B infection that builds on the 3-antigen conformation of the prophylactic HBV program, reformulated to enhance B and T cell responses. Developed in partnership with Brii Biosciences for the Asia-Pacific market.
• VBI-1901 A bivalent eVLP cancer vaccine immunotherapeutic candidate for glioblastoma (GBM) using CMV as a foreign viral antigen approach, expressing two highly-immunogenic CMV antigens (gB and pp65), co-administered with GM-CSF. Being evaluated in combination with GSK's proprietary AS01 adjuvant system.
• VBI-1501 A prophylactic eVLP vaccine candidate for cytomegalovirus (CMV) expressing a modified form of the gB antigen (gB-G), which elicits both fibroblast and epithelial cell neutralization. Target population includes newborns (congenital CMV) and immunocompromised individuals such as solid organ or bone marrow transplant recipients.
• VBI-2901 A multivalent pan-coronavirus vaccine candidate expressing spike antigens from SARS-CoV-2, SARS-CoV, and MERS-CoV on the surface of eVLP particles, designed to increase breadth of protection against COVID-19 and related coronaviruses. Demonstrated broad and durable protective titers against variants of concern.
• VBI-2902 A monovalent eVLP vaccine candidate expressing a modified, optimized, pre-fusion form of the SARS-CoV-2 (COVID-19) spike antigen. Developed with support from the Government of Canada Strategic Innovation Fund (CAD $56M) and CEPI funding (up to $33M).
• VBI-2905 A monovalent eVLP vaccine candidate expressing the pre-fusion spike protein from the Beta (B.1.351) variant of SARS-CoV-2. Developed with CEPI funding support.
• VBI-2501 A bivalent eVLP vaccine candidate for Zika consisting of a modified E glycoprotein and NS1 glycoprotein, designed to enhance neutralizing responses and T cell response.

Quantifiable outcome

• Phase 3 PROTECT study demonstrated superiority of 3-antigen HBV vaccine compared to Engerix-B in adults ≥45 years old
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• Brii Biosciences (Brii Bio)coreStrategic or Co-development Partner · 6 December 2018License and collaboration agreement for development of VBI-2601 (BRII-179) as part of a potential functional cure for chronic hepatitis B infection. Brii Bio paid $11 million upfront ($4M payment + $7M equity) and VBI is eligible for up to $117.5 million in milestones plus double-digit royalties on sales in China, Taiwan, Macau, and Hong Kong. In July 2023, worldwide license granted to Brii Bio with expected sale to Brii Bio by mid-2024.
• National Research Council of Canada (NRC)majorStrategic or Co-development PartnerCollaboration to develop COVID-19 vaccine candidate and pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS. Latest in a series of collaborations including research and development on preclinical programs.
• GlaxoSmithKline (GSK)majorStrategic or Co-development PartnerCollaboration to clinically evaluate combination of VBI-1901, VBI's cancer vaccine immunotherapeutic candidate, with GSK's proprietary AS01 adjuvant system in patients with recurrent glioblastoma (GBM).
• Syneos HealthcoreChannel Partner/ Reseller/ DistributorPartnership for commercialization of VBI's prophylactic hepatitis B program (PreHevbrio) in the U.S. Syneos Health provided commercial lead and support for U.S. commercialization.
• Resilience Biotechnologies Inc. (Resilience)majorStrategic or Co-development PartnerAgreement for development and manufacturing services in preparation for production of coronavirus vaccine candidates. Collaboration expected to support clinical studies through Phase 2 development.
• Adult Vaccine Access Coalition (AVAC)minorGTM or Marketing PartnerVBI is a corporate member of AVAC, formed to advocate for federal policies that improve access to and increase utilization of vaccines among adults.
• National Foundation for Infectious Diseases (NFID)minorGTM or Marketing PartnerVBI is a Silver Level Strategic Partner of NFID, supporting their work to educate the public and healthcare professionals about prevention, diagnosis, and treatment of infectious diseases.
• Association of Immunization Managers (AIM)minorGTM or Marketing PartnerVBI is a corporate alliance member of AIM, a nonprofit dedicated to establishing a nation free of vaccine-preventable disease.
• Immunize.orgminorGTM or Marketing PartnerVBI is a corporate member of Immunize.org (formerly Immunization Action Coalition) and supports its work to increase immunization rates by creating and distributing educational materials.
• Action Hepatitis Canada (AHC)minorGTM or Marketing PartnerVBI supports Action Hepatitis Canada, a national coalition responding to viral hepatitis, in their work to engage government, promote prevention, create awareness, and support community-based initiatives.
• Hepatitis B FoundationminorGTM or Marketing PartnerVBI supports the Hepatitis B Foundation's work on promoting disease awareness and immunization initiatives. HBF is a national nonprofit dedicated to finding a cure and improving quality of life for those affected by hepatitis B.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Novavax: Novavax is a vaccine biotechnology company developing recombinant protein nanoparticle vaccine technology, closely comparable to VBI's VLP platform. Both companies focus on virus-like particle and nanoparticle-based vaccines targeting infectious diseases.
• Valneva: Valneva is a specialty vaccine company developing prophylactic vaccines for infectious diseases with similar commercialization challenges and pipeline focus to VBI. Both companies target travel-related and emerging infectious disease indications with limited commercial-stage revenue.
• Dynavax Technologies: Dynavax Technologies is a vaccine-focused biopharmaceutical company developing novel vaccines and adjuvants, including the HEPLISAV-B hepatitis B vaccine. Comparable to VBI through its HBV vaccine competition and adjuvant-based approach to immune response enhancement.
• Bavarian Nordic: Bavarian Nordic is a vaccine company developing vaccines against infectious diseases and cancer immunotherapies. Both companies operate integrated vaccine development and manufacturing operations targeting similar infectious disease and oncology indications.

Broad incumbents

• Moderna: Moderna is a leading mRNA vaccine company directly comparable to VBI's MLE platform. Both companies leverage mRNA technology to drive vaccine antigen expression, though Moderna operates at significantly larger scale and capitalization.
• BioNTech: BioNTech is a major mRNA vaccine developer partnering with Pfizer for COVID-19 vaccines. The MLE platform VBI developed parallels BioNTech's mRNA approach but with additional in vivo eVLP particle formation, making them a relevant technology comparator.
• GlaxoSmithKline (GSK): GSK is a global vaccine leader manufacturing Engerix-B (single-antigen HBV vaccine used as comparator in VBI's PROTECT study) and supplying the AS01 adjuvant used in VBI's GBM program. Direct competitor in HBV vaccination and partner in VBI-1901 glioblastoma development.
• Sanofi Pasteur: Sanofi Pasteur is a major vaccine manufacturer with leadership in HBV and influenza vaccines, and a source of multiple senior VBI executives including CCO John Dillman and former Director Damian Braga. Represents the incumbent competitive and talent-development context for VBI.

Emerging players

• Arcturus Therapeutics: Arcturus Therapeutics is an mRNA vaccine developer with self-amplifying RNA technology comparable to VBI's MLE approach. Both companies focus on next-generation mRNA platforms for infectious disease applications.
• CureVac: CureVac is an mRNA vaccine company developing prophylactic vaccines and therapeutics. Comparable to VBI through mRNA-based vaccine technology and similar challenges in competing with larger mRNA platform companies like Moderna and BioNTech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vbivaccines
• Facebookfacebook.com/vbivaccines

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries6 records

Funding overview

Funding rounds26 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VBI Vaccines